Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kalvista Pharmaceuticals stock

Learn how to easily invest in Kalvista Pharmaceuticals stock.

Kalvista Pharmaceuticals is a biotechnology business based in the US. Kalvista Pharmaceuticals shares (KALV) are listed on the NASDAQ and all prices are listed in US Dollars. Kalvista Pharmaceuticals employs 105 staff and has a trailing 12-month revenue of around $3.8 million.

How to buy Kalvista Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – KALV. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with low fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Kalvista Pharmaceuticals stock price (NASDAQ: KALV)

Use our graph to track the performance of KALV stocks over time.

Kalvista Pharmaceuticals shares at a glance

Information last updated 2023-02-02.
Latest market close$8.33
52-week range$4.12 - $17.35
50-day moving average $6.27
200-day moving average $9.62
Wall St. target price$21.83
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.05

Buy Kalvista Pharmaceuticals stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Kalvista Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kalvista Pharmaceuticals price performance over time

Historical closes compared with the close of $8.33 from 2023-02-07

1 week (2023-02-02) 9.32%
1 month (2023-01-09) 26.21%
3 months (2022-11-09) 60.19%
6 months (2022-08-09) -35.82%
1 year (2022-02-08) -41.79%
2 years (2021-02-09) -75.13%
3 years (2020-02-07) 15.55
5 years (2018-02-09) 10.6126

Kalvista Pharmaceuticals financials

Revenue TTM $3.8 million
Gross profit TTM $-5,189,000
Return on assets TTM -32.49%
Return on equity TTM -49.49%
Profit margin 0%
Book value $5.85
Market capitalisation $264.3 million

TTM: trailing 12 months

Kalvista Pharmaceuticals share dividends

We're not expecting Kalvista Pharmaceuticals to pay a dividend over the next 12 months.

Have Kalvista Pharmaceuticals's shares ever split?

Kalvista Pharmaceuticals's shares were split on a 1:14 basis on 21 November 2016. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kalvista Pharmaceuticals shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Kalvista Pharmaceuticals shares which in turn could have impacted Kalvista Pharmaceuticals's share price.

Kalvista Pharmaceuticals share price volatility

Over the last 12 months, Kalvista Pharmaceuticals's shares have ranged in value from as little as $4.12 up to $17.345. A popular way to gauge a stock's volatility is its "beta".

KALV.US volatility(beta: 1.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kalvista Pharmaceuticals's is 1.0621. This would suggest that Kalvista Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Kalvista Pharmaceuticals overview

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Kalvista Pharmaceuticals is owned by insiders or institutions?
Currently 11.762% of Kalvista Pharmaceuticals shares are held by insiders and 88.077% by institutions.
How many people work for Kalvista Pharmaceuticals?
Latest data suggests 105 work at Kalvista Pharmaceuticals.
When does the fiscal year end for Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals's fiscal year ends in April.
Where is Kalvista Pharmaceuticals based?
Kalvista Pharmaceuticals's address is: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
What is Kalvista Pharmaceuticals's ISIN number?
Kalvista Pharmaceuticals's international securities identification number is: US4834971032
What is Kalvista Pharmaceuticals's CUSIP number?
Kalvista Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 141384107

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site